Clinical Trials Browser

INDUSTRY × Imatinib Mesylate × Thoracic × Clear all

NCT00171912 2017-02-23

Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes

MyeloidOther hematologic neoplasmSarcomaThoracic

Lung Neoplasms, Leukemia, Myelomonocytic, Chronic, Hypereosinophilic Syndrome, Dermatofibrosarcoma, Mastocytosis, Systemic, Leukemia, Myelomonocytic, Juvenile

NCT00154388 2016-11-18

Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases

Phase 2 Completed

185 enrolled

BreastDermatologicGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmOther solid neoplasmPlasma cellSarcomaThoracic

Malignant mesenchymal tumor, Adenocarcinoma, Brenner Tumor, Carcinoma, Renal Cell, Chondrosarcoma, Chordoma, Carcinoma, Adenoid Cystic, Fibroma, Hemangiopericytoma, Hemangiosarcoma, Leiomyosarcoma, Leukemia, Mast-Cell, Liposarcoma, Mastocytosis, Melanoma, Mesothelioma, Multiple Myeloma, Pleural Neoplasms, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Thymoma, Hypereosinophilic Syndrome, Sarcoma, Endometrial Stromal, Dermatofibrosarcoma, Rhabdomyosarcoma, Embryonal, Seminoma, Carcinoma, Ductal, Breast, Neurofibrosarcoma, Primary Myelofibrosis, Small Cell Lung Carcinoma